AI Platform Candidates
Dry Age-Related Macular Degeneration (AMD)
DiscoveryPlanned expansion of AI platform to discover next-gen candidates.
Key Facts
Indication
Dry Age-Related Macular Degeneration (AMD)
Phase
Discovery
Status
Planned expansion of AI platform to discover next-gen candidates.
Company
About Biophytis
Biophytis is a clinical-stage biotech focused on geroscience, aiming to treat age-related diseases by targeting the hallmarks of aging. Its core strategy revolves around three pillars: a proprietary AI-accelerated longevity research platform, the advanced Phase 3-ready program BIO101 for sarcopenia, and a parallel program for BIO101 in obesity as a combination therapy with GLP-1 agonists. The company has secured strategic partnerships and funding to advance its pipeline, including a landmark joint venture in Asia and an expanded AI collaboration with LynxKite.
View full company profile